| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| mslt 2 trial | 0.46 | 0.1 | 8518 | 63 | 12 |
| mslt | 0.7 | 0.5 | 5315 | 49 | 4 |
| 2 | 0.79 | 0.2 | 8772 | 26 | 1 |
| trial | 1.8 | 0.6 | 5931 | 29 | 5 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| mslt 2 trial | 0.67 | 0.5 | 324 | 80 |
| mslt 2 trial nejm | 1.95 | 0.9 | 2803 | 55 |
| mslt 2 trial melanoma | 1.25 | 0.5 | 8403 | 59 |
| mslt 1 and 2 trials | 1.88 | 0.4 | 7631 | 91 |
| select 2 trial nejm | 1.97 | 0.8 | 7048 | 69 |
| ttm 2 trial nejm | 1.98 | 0.3 | 8850 | 35 |
| select trial semaglutide nejm | 1.53 | 0.4 | 3341 | 87 |
| cross trial nejm 2012 | 0.33 | 0.8 | 5704 | 69 |
| step 1 trial nejm | 0.16 | 0.2 | 7451 | 80 |
| sglt2 inhibitors hfpef nejm | 1.09 | 0.1 | 9096 | 35 |
| keynote 522 nejm 2022 | 1.38 | 1 | 3819 | 94 |
| spm sej trial 2023 | 1.1 | 1 | 2595 | 64 |
| silveira mj nejm 2011 | 0.62 | 0.1 | 9257 | 61 |
| nejm guideline watch 2023 | 0.09 | 0.7 | 4449 | 48 |
| malt1 inhibitor clinical trial | 1.77 | 0.6 | 1299 | 59 |
| multiple myeloma review nejm | 0.59 | 0.4 | 8524 | 63 |
| multiple sclerosis clinical trial | 0.03 | 1 | 4579 | 55 |
| sglt2 heart failure trial | 1.78 | 0.1 | 8636 | 5 |
| sglt2 inhibitors clinical trials | 0.54 | 0.9 | 4460 | 95 |
| 10.1056/nejmra2216691 | 1.14 | 0.8 | 3067 | 82 |
| 10.1056/nejmra2002697 | 0.06 | 1 | 5039 | 12 |
| 10.1056/nejmsr2214184 | 0.01 | 0.4 | 5834 | 24 |
| 10.1056/nejmicm2101602 | 0.89 | 0.4 | 7580 | 25 |
| 10.1056/nejmra2213296 | 0.82 | 0.6 | 8744 | 4 |
| 10.1056/nejmra2026131 | 1.49 | 0.5 | 7151 | 88 |
| 10.1056/nejmra2103726 | 0.41 | 0.3 | 5082 | 29 |
| 10.1056/nejmra2120166 | 1.12 | 0.8 | 8105 | 95 |
